

INSIGHT

CC

INSULIN RECEPTOR BINDING

From venom peptides to a potential diabetes treatment

Cone snails have evolved a variety of insulin-like molecules that may help with the development of better treatments for diabetes.

JIŘÍ JIRÁČEK AND LENKA ŽÁKOVÁ

Related research article Ahorukomeye A, Disotuar MM, Gajewiak J, Karanth S, Watkins M, Robinson SD, Salcedo P, Smith NA, Smith BJ, Schlegel A, Forbes BE, Olivera B, Chou DH-C, Safavi-Hemami H. 2019. Fishhunting cone snail venoms are a rich source of minimized ligands of the vertebrate insulin receptor. *eLife* **8**:e41574. DOI: 10.7554/ eLife.41574

he hormone insulin is produced by the pancreas and is important for regulating the sugar levels in the blood. Defects in the production or function of insulin can lead to type 1 or type 2 diabetes, which affect millions of people worldwide. The lives of many of type 1 diabetics are dependent on daily insulin injections, which is also necessary for many type 2 diabetic patients (**Zaykov et al., 2016**).

The key to effective insulin treatment is fastacting drugs that can quickly deliver insulin to the target cells and mimic the way that the pancreas can regulate blood sugar levels. Natural insulin is first transported to the liver, where it inhibits the synthesis of glucose, and it only reaches the peripheral tissues later, where it eventually regulates the amount of glucose entering the cells.

However, insulin injections deliver the hormone directly to the periphery, which delays the inhibition of liver glucose production and causes fluctuations of blood sugar levels (*Herring et al.*, **2014**). Moreover, at high concentrations, insulin can form aggregates that take time to dissolve and consequently contribute to delaying its action after injection (*Figure 1*, upper panel; *Baker et al., 1988*). Developing faster treatments that are not prone to aggregation is a top priority, and although several fast-acting insulins are in clinical use, they still have not reached the same pharmacodynamics as natural insulin secreted by the pancreas (*Herring and Russell-Jones, 2018; Zaykov et al., 2016*).

Previous studies were able to identify the structure of the complex that insulin forms with its receptor, and the basics of how insulin binds the receptor (De Meyts, 2015; to Menting et al., 2013; Menting et al., 2014; Scapin et al., 2018; Weis et al., 2018). Now, in eLife, Helena Safavi-Hemami of the University of Utah School of Medicine and colleagues including Peter Ahorukomeye and Maria Disotuar as joint first authors - report how cone snails could help progress our understanding of this process (Ahorukomeye et al., 2019).

Cone snails have evolved sophisticated strategies for hunting fish. They produce venomous, insulin-like molecules, which they release into the water to paralyze their victim (*Figure 1*, lower panel). The insulin-like molecules induce low blood sugar levels in their prey, which makes them unable to escape. It has previously been shown that the insulin-like peptide of a cone snail species does not form aggregates (*Menting et al., 2016*). Therefore, the researchers – who are based at institutes in the United States and Australia – wanted to find out if other cone snails also produced similar substances.

Ahorukomeye et al. discovered that although the species they analyzed made a range of

Copyright Jiráček and Žáková. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.




Figure 1. Insulin receptor binding in humans and cone snails. Upper panel: Insulin is secreted by the pancreas in the form of hexamer aggregates with ions (Zn²⁺) at their center: these aggregates divide to form dimers, which then split to form monomers. Each monomer consists of an A chain (red) and a B chain (gray) with a C-terminal B23-B30 strand. An insulin monomer binds to the L1 domain of an insulin receptor, with the C-terminus of the B chain partially detaching from the central core of the monomer to avoid a clash with the CT peptide (blue) of the receptor. A phenylalanine amino acid residue at the position B24 of insulin (PheB24, black) is crucial for insulin binding. Lower panel: Fish-hunting cone snails secrete insulin-like molecules that do not form aggregates. These molecules induce low blood sugar levels in fish, which stops them escaping. Although cone snail insulin lacks both the C-terminal of the B-chain (gray) and PheB24, it can still bind to fish insulin receptors because it contains two tyrosine amino acid residues (TyrB16 and TyrB20, black) that mimic the missing interactions. The A-chain is shown in beige.

different versions of these insulin-like peptides, none of the molecules could form aggregates. Moreover, the peptides were able to bind to human insulin receptors, and they were also effective in fish and mouse models of the disease, where they reversed high blood sugar levels. Structural and molecular analyses further revealed that the insulin-like peptides of the snails bind in an unusual way to the insulin receptor.

Previous research has shown that a region of insulin that is involved in the cluster formation, the C-terminus of the B chain, is also crucial for binding to the insulin receptor (*Figure 1*, upper panel; *Baker et al., 1988; Menting et al.,* 2014). However, attempts to remove the B chain to avoid cluster formation have so far compromised the function of insulin.

Ahorukomeye et al. discovered that although the insulin-like peptides produced by the snails lacked the C-terminal part of the B chain, they could still effectively interact with the human insulin receptor. This might be because some their peptides contained hydrophobic amino acid residues that mimic important receptorbinding regions (e.g., phenylalanine at the position B24 of insulin) that had been lost with the missing C-terminal segment (*Figure 1*, lower panel). Moreover, these regions were very similar among the cone snail species studied. Taken together, these findings indicate that the C-terminus of the B chain is not necessary for insulin binding to the receptor. Future research may build on these results to design potent, fast-acting insulin agonists that are less likely to form aggregates.

The study of Ahorukomeye et al. highlights the beauty of evolution and the adaptability of organisms. We can learn important lessons from Nature as we seek to develop more patientfriendly insulin receptor agonists for the treatment of diabetes. Jiří Jiráček is in the Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic

jiracek@uochb.cas.cz

b http://orcid.org/0000-0003-3848-2773

Lenka Žáková is in the Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic

zakova@uochb.cas.cz

Competing interests: The authors declare that no competing interests exist.

Published 12 February 2019

References

Ahorukomeye A, Disotuar MM, Gajewiak J, Karanth S, Watkins M, Robinson SD, Salcedo P, Smith NA, Smith BJ, Schlegel A, Forbes BE, Olivera B, Chou DH, Safavi-Hemami H. 2019. Fish-hunting cone snail venoms are a rich source of minimized ligands of the vertebrate insulin receptor. *eLife* **8**:e 41574. DOI: https://doi.org/ 10.7554/eLife.41574

Baker EN, Blundell TL, Cutfield JF, Cutfield SM, Dodson EJ, Dodson GG, Hodgkin DM, Hubbard RE, Isaacs NW, Reynolds CD. 1988. The structure of 2zn pig insulin crystals at 1.5 Å resolution. *Philosophical Transactions of the Royal Society of London B, Biological Sciences* **319**:369–456. DOI: https://doi.org/

10.1098/rstb.1988.0058, PMID: 2905485 **De Meyts P**. 2015. Insulin/receptor binding: the last piece of the puzzle? *BioEssays* **37**:389–397. DOI: https://doi.org/10.1002/bies.201400190 **Herring R**, Jones RH, Russell-Jones DL. 2014. Hepatoselectivity and the evolution of insulin. *Diabetes, Obesity and Metabolism* **16**:1–8. DOI: https://doi.org/10.1111/dom.12117, PMID: 2367

9086 Herring R, Russell-Jones DDL. 2018. Lessons for

modern insulin development. *Diabetic Medicine* **35**: 1320–1328. DOI: https://doi.org/10.1111/dme.13692, PMID: 29802638 Menting JG, Whittaker J, Margetts MB, Whittaker LJ, Kong GK, Smith BJ, Watson CJ, Záková L, Kletvíková E, Jiráček J, Chan SJ, Steiner DF, Dodson GG, Brzozowski AM, Weiss MA, Ward CW, Lawrence MC. 2013. How insulin engages its primary binding site on the insulin receptor. *Nature* **493**:241–245. DOI: https://doi.org/10.1038/nature11781, PMID: 23302862

Menting JG, Yang Y, Chan SJ, Phillips NB, Smith BJ, Whittaker J, Wickramasinghe NP, Whittaker LJ, Pandyarajan V, Wan Z-I, Yadav SP, Carroll JM, Strokes N, Roberts CT, Ismail-Beigi F, Milewski W, Steiner DF, Chauhan VS, Ward CW, Weiss MA, et al. 2014. Protective hinge in insulin opens to enable its receptor engagement. PNAS **111**:E3395–E3404. DOI: https:// doi.org/10.1073/pnas.1412897111

Menting JG, Gajewiak J, MacRaild CA, Chou DH, Disotuar MM, Smith NA, Miller C, Erchegyi J, Rivier JE, Olivera BM, Forbes BE, Smith BJ, Norton RS, Safavi-Hemami H, Lawrence MC. 2016. A minimized human insulin-receptor-binding motif revealed in a *Conus* geographus venom insulin. *Nature Structural & Molecular Biology* **23**:916–920. DOI: https://doi.org/ 10.1038/nsmb.3292, PMID: 27617429

Scapin G, Dandey VP, Zhang Z, Prosise W, Hruza A, Kelly T, Mayhood T, Strickland C, Potter CS, Carragher B. 2018. Structure of the insulin receptor-insulin complex by single-particle cryo-EM analysis. *Nature* 556:122–125. DOI: https://doi.org/10.1038/ nature26153, PMID: 29512653

Weis F, Menting JG, Margetts MB, Chan SJ, Xu Y, Tennagels N, Wohlfart P, Langer T, Müller CW, Dreyer MK, Lawrence MC. 2018. The signalling conformation of the insulin receptor ectodomain. *Nature Communications* **9**:4420. DOI: https://doi.org/10. 1038/s41467-018-06826-6, PMID: 30356040

Zaykov AN, Mayer JP, DiMarchi RD. 2016. Pursuit of a perfect insulin. *Nature Reviews Drug Discovery* **15**: 425–439. DOI: https://doi.org/10.1038/nrd.2015.36, PMID: 26988411